Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV

This study has been completed.
Sponsor:
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00952133
First received: July 30, 2009
Last updated: February 13, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to determine if subjects who receive Palonosetron plus Dexamethasone have less post-operative nausea and vomiting (PONV) than those who receive Palonosetron alone.


Condition Intervention Phase
PONV
Drug: Placebo Comparator
Drug: Palonosetron with Dexamethasone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Randomized Double Blind Study to Evaluate the Efficacy of IV Palo w/ IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed Post-Operative Nausea/Vomiting in Subj Undergoing Laparoscopic Surgeries w/a High Emetogenic Risk

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • Complet Response Rate [ Time Frame: Pre-op through 72 hours post emergence from anesthesia ] [ Designated as safety issue: Yes ]
    A Complete Response (CR): defined as no nausea, no vomiting/retching, no rescue medication and no withdrawal of consent from the time of administration of the study drug(s) until 72 hours post emergence from anesthesia.


Secondary Outcome Measures:
  • Number of Participants Who Experienced no or Reduced PONV the First 96 Hours After Surgery [ Time Frame: Pre-op through 96 hours post-op ] [ Designated as safety issue: Yes ]
    Participants with no or reduced post operative nausea over a 96 hour period after surgery. questionnaires answered after surgery at 2 hour, 6 hour, 12 hour 72 hour and 96 hours post surgery.


Enrollment: 118
Study Start Date: July 2009
Study Completion Date: April 2011
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Palonosetron with Dexamethasone
Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 5mg IV Dexamethasone (Decadron) before surgery.
Drug: Palonosetron with Dexamethasone
Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 5mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
Other Names:
  • Palonosetron
  • Aloxi
  • Dexamethasone
  • Decadron
Placebo Comparator: Palonosetron and Placebo
Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Intravenous Palonosetron and Saline solution
Drug: Placebo Comparator
The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
Other Names:
  • Palonosetron
  • Placebo

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has signed an informed consent form
  • Have an ASA Physical Status Classification of I, II, or III
  • Female, 18-55 years old

    • surgically sterilized, or
    • pre-menopausal, with a negative pregnancy test within 7 days before study medication administration
  • Male, 18-55 years old, who has more than 3 risk factors for PONV
  • Undergoing outpatient laparoscopic gynecological surgery or laparoscopic abdominal surgery, scheduled for between 1 and 3 hours duration
  • Known to have a history of post-operative nausea and vomiting and/or a history of motion sickness
  • Has been a non-smoker for at least the previous 12 consecutive months
  • Is able and willing to complete a subject diary until the end of the 96 Hour Follow-Up Assessment period
  • Will be available to respond to follow-up by study personnel at 72 and 96 hours post emergence from anesthesia

Exclusion Criteria:

  • Has an ASA Physical Status Classification of IV or V
  • Is pregnant or breastfeeding
  • Has been taking more than 10-15mg of oxycodone, or an equivalent opioid dose, on a regular, daily basis, for more than 3 consecutive days before surgery
  • Has received an investigational drug in the precious 30 days or who is schedule to receive any investigational drug during the study period
  • Has persistent or recurrent nausea and/or vomiting due to other etiologies, including but not limited to, gastric outlet obstruction, hypercalcemia, active peptic ulcer, increased intracranial pressure, or brain metastases
  • Experienced retching or vomiting or uncontrolled nausea within 48 hours before administration of study drug
  • Received medication with known or potential antiemetic activity within 24 hours before receiving study drug. This includes, but is not limited to: phenothiazines, butyrophenones, hydroxyzine, lorazepam, cannabinoids, metoclopramide, corticosteroids (with the exception of topical steroids for skin disorder and inhaled steroids for respiratory disorders), trimethobenzamide, monoamine oxidase inhibitors, lithium, and 5-HT3 receptor antagonists. Subjects who might require one or more of these medications during the 24-hour treatment period, other than as described in this protocol, are also excluded.

    • Note: benzodiazepines other than lorazepam are allowed within 24 hours before and during study period, but only when used for indications such as anxiety or to induce sleep.
  • Received radiation therapy to abdomen or pelvis in the 7 days prior to receiving study medication and/or will receive radiation therapy to abdomen or pelvis in the evaluation period.
  • Has a history of poorly controlled diabetes mellitus
  • Has a history of wound dehiscence
  • Has had an incidence of necrotizing fasciitis, or any similar infectious process, within the previous 90 days
  • Has a know systemic fungal infection, history of tuberculosis, or other mycobacterial infection
  • Is immunocompromised - defined as a WBC count of <3,000 mm3
  • Has any current or past medical condition (e.g., vagotomy) and/or require medication to treat a condition that could confound the evaluation of the data collected in this clinical trail
  • Has a known hypersensitivity or contraindication to palonosetron hydrochloride or any another 5-HT3 receptor antagonist, dexamethasone, or any scheduled anesthetic or analgesic agents
  • Has a known hypersensitivity to fentanyl and/or ketorolac tromethamine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00952133

Locations
United States, New York
NYU Langone Medical Center
New York, New York, United States, 10016
Sponsors and Collaborators
New York University School of Medicine
Eisai Inc.
Investigators
Principal Investigator: Jeanna Blitz, MD NYU School of Medicine
Study Director: Michael Haile, MD NYU School of Medicine
  More Information

Additional Information:
Publications:
Responsible Party: New York University School of Medicine
ClinicalTrials.gov Identifier: NCT00952133     History of Changes
Other Study ID Numbers: H08-605
Study First Received: July 30, 2009
Results First Received: June 22, 2012
Last Updated: February 13, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by New York University School of Medicine:
PONV
Outpatient surgery
Laparoscopic abdominal surgery
Laparoscopic gynecologic surgery

Additional relevant MeSH terms:
Dexamethasone acetate
Dexamethasone
Dexamethasone 21-phosphate
BB 1101
Palonosetron
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on July 31, 2014